From this constrained selection of studies, it appears that tecovirimat is well-tolerated and might prove to be an effective antiviral treatment for MPX. To better grasp the significance of antiviral treatment in managing human monkeypox cases, more studies are required. The Journal of Drugs and Dermatology featured a study on medications for skin conditions. An article, designated with the Digital Object Identifier (DOI) 10.36849/JDD.7263, was part of the 22nd volume, 3rd issue of a journal published in 2023.
The limited data from these studies supports the notion that tecovirimat may be a safe and potentially effective antiviral treatment for monkeypox. To elucidate the therapeutic efficacy of antivirals for human monkeypox, further clinical trials are required. Dermatological drugs were the subject of the J Drugs Dermatol article. The article documented by the DOI 10.36849/JDD.7263 appeared in journal volume 22, issue 3 of 2023.
Topical calcipotriene, when followed by topical betamethasone dipropionate, has been found to produce a more considerable improvement compared to the utilization of either topical treatment alone. A topical, fixed-combination formulation of calcipotriene 0.005% and betamethasone dipropionate 0.064% in a cream base, known as Cal/BD cream, demonstrates high patient satisfaction regarding convenience and tolerability. This study contrasts patient experiences and satisfaction with Cal/BD foam and Cal/BD cream. Twenty subjects in an open-label, single-use, split-body study are involved. Ten subjects also suffered from scalp psoriasis, an additional condition. The investigator, employing a randomized approach, applied the study treatments, while patients concurrently completed questionnaires that assessed their treatment preferences.
Cal/BD formulations produced a prompt and considerable improvement in symptoms including pruritus, stinging, burning, and pain, without any statistically appreciable difference between the two treatment options. Cal/BD cream's vehicle performance and patient satisfaction scores significantly surpassed those of Cal/BD foam in several critical measurements. Subjects applying Cal/BD to areas other than the scalp overwhelmingly favored the cream formulation, representing 55% of the total. Of those studied, 60% demonstrated a preference for Cal/BD cream versus Cal/BD foam in terms of scalp care. During the trial, there was no mention of adverse events among the participants.
High patient satisfaction with Cal/BD cream and a marked preference for its cream base over foam are indicated in the findings of this current study, specifically concerning the treatment of body and scalp psoriasis. A Dermatology Journal covering Drugs. A paper in the 2023 edition, 22nd volume, issue 3, of a certain journal, was documented by the DOI 10.36849/JDD.7165.
Patient responses in this study consistently indicate a strong preference for the Cal/BD cream base over the foam, resulting in high satisfaction levels for managing body and scalp psoriasis. Studies on the interaction between drugs and the skin are commonly presented in the Journal of Drugs and Dermatology. Journal of Dermatology and Diseases, volume 22, number 3, 2023, hosted article 7165, referenced by DOI 10.36849/JDD.7165.
A highly pathogenic betacoronavirus, SARS-CoV-2, was officially named COVID-19 by the World Health Organization (WHO) on February 11, 2020, and infects humans. Genetic predisposition is a recognized contributor to the emergence of AA, a tissue-specific autoimmune disease, as demonstrated by compelling evidence. Psycho-emotional stress, regardless of its duration (acute or chronic), could initiate or worsen AA in a number of patients.5 Psychological stress is suspected to activate or worsen skin inflammation through the neuroendocrine system, which plays a crucial role in connecting the brain to the skin.67 The recovery process from COVID-19 infection is sometimes accompanied by hair loss, a frequently observed side effect in many patients.
A growing enthusiasm for cosmetic procedures conducted in an outpatient setting is notable in modern society. These procedures employ topical anesthetics as their chosen form of anesthesia. Standalone or integrated into a multifaceted anesthetic strategy, these tools are applicable. Topical anesthetics, while offering numerous advantages, are not without potential drawbacks, including the risk of toxicity. check details The cosmetic dermatology application of topical anesthetics is the central focus of this paper. Cosmetic dermatologists were surveyed regarding their use of topical anesthetics in their clinical practice. Our investigation revealed that a combination of benzocaine 20%, lidocaine 6%, and tetracaine 4% was the anesthetic most frequently chosen. Survey respondents most often cited fractionally ablative lasers and fractionally non-ablative lasers as procedures utilizing topical anesthetics for anesthesia. Although most surveyed dermatologists experienced no difficulties with the topical anesthetic, a contingent reported adverse events arising in a portion of their patients. The application of topical anesthetics in cosmetic dermatology is important, enabling both patient comfort and the avoidance of more extensive anesthetics. Further research is imperative for the continued advancement of this dynamic area of cosmetic dermatology. Dermatological research involving pharmaceuticals is frequently published in the Journal of Drugs and Dermatology. Within the third issue of the 22nd volume, published in 2023, the article with DOI 10.36849/JDD.6978 is found.
The physiological processes of the hair follicle, amongst others, are impacted by the pleiotropic hormone melatonin. We endeavor to pinpoint scientific evidence confirming the potential benefits of melatonin for human hair growth.
The collected data on the potential link between melatonin and hair health, indicated by hair follicle development, is summarized.
Studies examining the link between melatonin and hair loss, as identified in a 2022 literature review, utilized data from three databases: PubMed, Google Scholar, and Cochrane. check details Searching for hair, hair loss, alopecia, hair growth, effluvium, and scalp was performed simultaneously with the search term melatonin. Two separate reviewers independently screened studies according to predefined inclusion criteria. Data gathering procedures involved noting demographics, details about melatonin intervention, the specific study type, and the impact observed on hair.
Eleven human studies on melatonin use identified 2267 subjects (1140 male) diagnosed with alopecia. Topical melatonin usage led to positive outcomes in eight of the examined studies for subjects experiencing androgenetic alopecia (AGA). Improvements in scalp hair growth (n=8), hair density (n=4), and hair shaft thickness (n=2) were observed in melatonin users, as reported by various studies, when compared to control participants. A 0.0033% or 0.1% topical melatonin solution applied once a day for 90 to 180 days may offer comparable effects to 15 mg of oral melatonin taken twice daily for the same 180-day period.
Evidence suggests that melatonin may aid in the promotion of scalp hair growth, particularly in men experiencing androgenetic alopecia. Further investigations are warranted, incorporating a greater number of patients and exploring the precise mechanism of action. J Drugs Dermatol. publishes articles on the relationship between drugs and skin diseases. In 2023, volume 22, issue 3, of a journal, the paper with the DOI 10.36849/JDD.6921 was published.
Melatonin's potential to induce scalp hair regrowth, particularly in men experiencing androgenetic alopecia, is corroborated by available research. check details To advance understanding, future research endeavors must include a more extensive patient sample size and examine the mechanism of action in detail. Dermatological drugs were extensively studied in J Drugs Dermatol. The article with the doi1036849/JDD.6921 identifier was showcased in the 2023, volume 22, number 3 of the journal.
TikTok provides a platform for its users to share and view brief video content encompassing diverse subjects, dermatology being one such area. This project undertook a comprehensive analysis of TikTok video sources concerning the treatment of four skin conditions and tabulated the percentage of posts by board-certified dermatologists.
On July 16th, 2021, the TikTok application's search function received the following hashtags inputted by an investigator: #AcneTreatment, #EczemaTreatment, #PsoriasisTreatment, and #RosaceaTreatment. The comprehensive set of 400 videos, once collected, was subsequently segregated into distinct categories based on the video poster's professional background: dermatologist, dermatology resident, non-dermatologist physician, physician assistant, nurse practitioner, registered nurse, esthetician, patient, beauty blogger, and any other classification. Videos ineligible for inclusion were those not in English, paid advertisements or from a commercial page, and/or not directly related to dermatologic treatment or education.
Across all analyzed videos, the top contributors were patients (408%), significantly more frequent than dermatologists (168%). Of the videos examined, a significant 373% were uploaded by credentialed professionals, while the remaining 627% originated from individuals lacking formal qualifications. The overwhelmingly prevalent topic among licensed professionals' posts, regarding the four conditions, was acne, which comprised 524% of the discussions. Non-professional posters' posts disproportionately highlighted psoriasis (867%) and eczema (667%) compared to the other two conditions.
To encourage interaction with dermatological content from board-certified dermatologists on platforms like TikTok, more educational content, crafted by dermatologists, is vital. The journal, J Drugs Dermatol., delves into the world of dermatological pharmaceuticals. The referenced research, published in 2023's volume 22(3) is further identified by DOI 10.36849/JDD.6676.
To foster interaction with board-certified dermatologists' dermatologic content on TikTok and other digital venues, an augmentation in dermatologist-generated educational content is essential. Research published in J Drugs Dermatol. Research from the Journal of Diseases & Disorders, 2023, volume 22, number 3, is accessible by the DOI 10.36849/JDD.6676.